GeoVax Labs, Inc.

GOVX

US3736786068

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-17 EDT			5-day change	1st Jan Change
3.02 ^USD	+2.03%		-5.62%	-44.23%

07-16	Roth MKM Initiates GeoVax Labs at Buy With $20 Price Target	MT
07-16	Top Premarket Gainers	MT

GeoVax Labs, Inc. will Change its Ticker to GOVX.D from GOVX

January 24, 2020 at 12:00 am

Effective January 24, 2020, GeoVax Labs, Inc. will change its Pink Sheets LLC stock ticker symbol to GOVX.D from GOVX.

Latest news about GeoVax Labs, Inc.

Roth MKM Initiates GeoVax Labs at Buy With $20 Price Target	07-16	MT
Top Premarket Gainers	07-16	MT
Geovax Labs, Inc. Receives Barda Project NextGen Award to Conduct Phase 2B Clinical Study Evaluating the Company's Next-Generation Covid-19 Vaccine Candidate, GEO-CM04S1	06-18	CI
Top Premarket Decliners	06-07	MT
Transcript : GeoVax Labs, Inc., Q1 2024 Earnings Call, May 14, 2024	05-14
GeoVax Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress	03-28	CI
GeoVax Labs, Inc. Achieves Milestone in Transition to Commercially Validated Manufacturing System	03-06	CI
Transcript : GeoVax Labs, Inc., Q4 2023 Earnings Call, Feb 29, 2024	02-29
GeoVax Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
GeoVax Labs Gets Two Patents from US Patent and Trademark Office	02-13	MT
Geovax Reports Positive Interim Data from Phase 2 Clinical Trial of Geo-Cm04s1 as A Universal Covid-19 Vaccine Booster	02-06	CI
Transcript : GeoVax Labs, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 02:30 PM	01-08
Geovax Appoints Marc Pipas as Executive Medical Director, Oncology	01-08	CI
GeoVax Labs, Inc. Announces Gedeptin Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients	01-04	CI
GeoVax Labs Files for 21.1 Million Share Offering by Selling Shareholder	01-02	MT
Geovax Labs, Inc. Announces the Presentation of Preclinical Vaccine Efficacy Data for GEO-CM02	11-14	CI
Transcript : GeoVax Labs, Inc., Q3 2023 Earnings Call, Nov 08, 2023	11-08
GeoVax Labs, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
GeoVax Labs, Inc. Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine	23-10-30	CI
GeoVax Labs Gets Notice of Allowance for US Patent Application Covering Marburg Vaccine	23-10-09	MT
GeoVax Labs' HIV Vaccine Patent Gets Notice of Allowance from US Patent and Trademark Office	23-10-05	MT
GeoVax Labs, Inc. Secures Multi-Product License for Probiogen's Age1.Cr.Pix(R) Suspension Cell Line to Bolster MVA-Based Vaccine Development	23-09-26	CI
Geovax Labs, Inc. Next-Generation Covid-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients	23-09-19	CI
GeoVax Labs, Inc. Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster	23-09-11	CI

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Companyâs portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.

Sector

Biotechnology & Medical Research

Calendar

12:00pm - Emerging Growth Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.02 USD

Average target price

11.33 USD

Spread / Average Target

+275.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GEOVAX LABS, INC.	-44.23%	14M
MODERNA, INC.	+24.74%	47.54B
IQVIA HOLDINGS INC.	-0.47%	41.96B
LONZA GROUP AG	+49.45%	41.55B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	30.36B
CELLTRION, INC.	-4.47%	28.7B
ICON PUBLIC LIMITED COMPANY	+17.96%	27.61B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.7B
MEDPACE HOLDINGS, INC.	+42.56%	13.51B
BIO-TECHNE CORPORATION	+1.46%	12.34B

Other Biotechnology & Medical Research

GeoVax Labs, Inc.

Equities

GOVX

US3736786068

Biotechnology & Medical Research

GeoVax Labs, Inc. will Change its Ticker to GOVX.D from GOVX

Latest news about GeoVax Labs, Inc.

Chart GeoVax Labs, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research